Published Study Documents Biologic Potential of Cellular Compositions
from Harvest Technologies’ BMAC System™
PLYMOUTH, Mass. (Business Wire EON) April 7, 2008 --
Harvest Technologies Corp. (www.harvesttech.com)
announced today the publication of results from a study designed to
document the biologic potential of cellular compositions derived from
its Harvest
BMAC
System (http://www.harvesttech.com/pdf/technprofile_v5_111606.pdf).
The study appears in the peer-reviewed scientific journal, Cell
Transplantation (Heeschen et al, Vol. 16, pp 1059-1069), under
the title, “Concentration of Bone Marrow Total
Nucleated Cells by a Point-of-Care Device Provides a High Yield and
Preserves Their Functional Activity”.
There has been considerable excitement generated concerning the
potential of bone marrow cells to be effective in regenerating damaged
tissue; however, it is important to demonstrate that the method for
isolating these cells does not impair their regenerative potential.
Harvest Technologies undertook this study to certify that its method of
concentrating bone marrow cells does not change their functional ability.
“The results of this study are important
because not all bone marrow cell compositions are the same,”
said the study’s principal investigator,
Pr. Christopher Heeschen, Dept. of Surgery, Ludwig-Maximilians
University, Munich, Germany. “In our
experience, different methods used to process bone marrow cells can lead
to different cell compositions, and those different cell compositions
can have different clinical effects. Therefore, we believe that
before a new method of processing bone marrow is used in a clinical
study, it must be evaluated to document its biologic potential.”
“We believe this is the first time that the
cell composition of a simple point-of-care system has been compared to
the cell composition prepared by the recognized gold standard, the
Ficoll method, in a rigorous study whose results were then published in
a peer-reviewed scientific journal,” said Gary
Tureski, President of Harvest Technologies. “A
rigorous and independent study of point-of-care compositions that have
been evaluated for their biologic potential is obligatory, if not
mandatory. The Heeschen study demonstrates that the Harvest BMAC System
is, in fact, capable of producing a bone marrow cell composition that is
equal to, and may in fact be clinically superior to, the cell
composition prepared by the gold standard.”
Until now, it has been difficult to process and concentrate a
clinically significant dose of adult stem cells from a patient’s
bone marrow at the point of care. The Harvest Technologies BMAC
System is the world’s first
technology that produces clinically significant amounts of stem and
precursor cells from a small aspirate of autologous bone marrow in just
15 minutes.
Harvest
Technologies is a privately held company based in Plymouth, Mass.
Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/U3VtbS1IYWxmLVRoaXItU3VtbS1TdW1tLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
